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Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) have been associated with upper gastrointestinal (GI) bleeding.
Given their worldwide use, even small risks account for a large number of cases. This study has been conducted with
carefully collected information to further investigate the relationship between SSRIs and upper GI bleeding.
Methods: We conducted a case-control study in hospitals in Spain and in Italy. Cases were patients aged $18 years with a
primary diagnosis of acute upper GI bleeding diagnosed by endoscopy; three controls were matched by sex, age, date of
admission (within 3 months) and hospital among patients who were admitted for elective surgery for non-painful disorders.
Exposures to SSRIs, other antidepressants and other drugs were defined as any use of these drugs in the 7 days before the
day on which upper gastrointestinal bleeding started (index day).
Results: 581 cases of upper GI bleeding and 1358 controls were considered eligible for the study; no differences in age or
sex distribution were observed between cases and controls after matching. Overall, 4.0% of the cases and 3.3% of controls
used an SSRI antidepressant in the week before the index day. No significant risk of upper GI bleeding was encountered for
SSRI antidepressants (adjusted odds ratio, 1.06, 95% CI, 0.57–1.96) or for whichever other grouping of antidepressants.
Conclusions: The results of this case-control study showed no significant increase in upper GI bleeding with SSRIs and
provide good evidence that the magnitude of any increase in risk is not greater than 2.
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Introduction
Acute upper gastrointestinal (GI) bleeding is a prevalent and
clinically significant condition with important implications for
health care costs worldwide. In the United States, more than
400,000 hospital admissions per year for upper GI bleeding are
estimated to occur, and mortality ranges between 3% and 14%
[1]; this has not changed in the past 10 years and increases with
increasing age. Known risk factors for peptic ulcer bleeding are
non-steroidal anti-inflammatory drugs (NSAIDs) use and Helico-
bacter pylori infection.
More recently, selective serotonin reuptake inhibitors (SSRIs)
have been identified as another risk factor [2], and since then, 15
additional studies –including this one– addressing this topic have
been carried out [3–16]. Albeit four studies found a strong
significant association between SSRIs and upper GI bleeding (a
risk value higher than 2) [2,5,7,11], others found no association at
all [3,8,10]; thereby, the association remains a matter of
controversy.
The widespread use of antidepressants, particularly SSRIs,
makes even small risks account for a large number of cases,
converting this problem into an important public health issue. This
fact, along with the lack of consistency of the findings in the studies
carried out so far, has aroused a great interest on this subject. Our
study has been conducted with carefully collected information to
further understand the relationship between SSRIs and upper GI
bleeding in the framework of a general study on risk factors of
upper GI bleeding.
Methods
Study design
We conducted a, multicentre, case-control study in 4 hospitals
in Spain and 1 in Italy. Patients were recruited from January 2004
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to July 2006 in Spain and from October 2005 to November 2007
in Italy; the population covered by these hospitals was 1,570,687
inhabitants.
Cases and controls
Records of all endoscopic procedures and lists of admission
diagnosis in the participating hospitals were examined daily. Cases
were patients aged $18 years who were admitted with a primary
diagnosis of acute upper GI bleeding from a duodenal or gastric
ulcer, acute lesions of the gastric mucosa, erosive duodenitis or
mixed lesions, all of them diagnosed by endoscopy; patients with
endoscopic diagnosis other than bleeding from the above specified
lesions were excluded from the study. For each case, up to 3
controls $18 year-old, matched by sex, age (65 years), date of
admission (within 3 months) and hospital were selected; they were
recruited from patients who were admitted for elective surgery for
non-painful disorders, including inguinal hernia, prostate adeno-
ma and cataracts. According to the null hypothesis approach, they
were expected to have a prevalence of drug use similar to that of
the underlying population from which the cases arise. All subjects,
regardless of their condition of case or control, who at the start
date had a history of cancer, coagulopathy, Mallory-Weiss
syndrome and esophageal varices, were excluded; those who were
non-residents in the study area and those with no reliable interview
were also excluded. An upper GI bleeding odds ratio of 2 could be
detected with a power of 80% with 500 cases and 1500 controls
(crude power calculation), assuming a prevalence of SSRI use of
4% (alpha error 5%).
Information retrieval and exposure definition
After obtaining an informed consent, especially trained
monitors interviewed patients with a structured questionnaire
within 15 days of admission; this questionnaire had several
questions about previous use and frequency of use of medicines,
with a series of colour pictures including the agents of interest. The
interview included detailed information on symptoms leading to
the current admission, and on the clinical and medication history.
Exposures to SSRIs, other antidepressants and other drugs were
defined as any use of these drugs which lasted until the index date
or when discontinued within 7 days before the index date (the day
on which first symptoms of upper GI bleeding started). For each
case, the index date was defined blindly to the use of drugs;
consumption of medications between index dates and interview
dates was not taken into account for the purpose of defining
exposures (i.e., comsumption of medications could be altered by
the presence of the first signs of disease). For controls, index date
was the day of the interview.
To estimate the association with upper GI bleeding, different
groups were established. As a first approach, antidepressants were
considered all together; then, antidepressants were classified into
three groups according to their affinity for the serotonin
transporter, i.e., high affinity (fluoxetine, paroxetine, sertraline
and clomipramine), intermediate affinity (amitriptyline, fluvox-
amine, citalopram, imipramine, dosulepin, venlafaxine, duloxe-
tine, escitalopram and melitracen) and low affinity (mirtazapine,
nortriptyline, desipramine, trimipramine, maprotiline, trazodone,
mianserin, amoxapine, bupropion, doxepin, moclobemide, ciclo-
benzaprine and etoperidone) [17]; lastly, antidepressants were
classified according to selectivity, which in turn was based on the
ratio of the equilibrium dissociation constants for the serotonin
over the noradrenaline transporter; thus, for SSRIs (ATC class
N06AB), sertraline, fluoxetine, fluvoxamine, paroxetine, citalo-
pram, etoperidone and escitalopram were grouped; for non-
SSRIs, amitriptiline, dosulepin, trimipramine, doxepine, mapro-
tiline, amoxapine, imipramine, nortriptiline and clomipramine
were grouped; and for other antidepressants, the rest of active
ingredients were grouped.
Main outcome measures and statistical analysis
Adjusted odds ratios (OR) and their 95% confidence intervals
(95% CI) were estimated by means of a generalised linear mixed
model for dependent binomial-type variables (case or control) [18].
This approach has three advantages over the application of
conditional logistic regression: (i) it takes into account the
multicentre character of the study when the models are developed;
(ii) it allows to take advantage of the information of the strata (each
case and its matched controls) containing only cases or controls;
and (iii) all members have identical values for the covariates [18].
In the construction of the model, patients were taken as level
one, strata as level two, and hospitals as level three. In the
estimation of the models we used the lmer function, implemented
in the context of the lme4 R package (version 2.7.2) [19]. This
function performs the fit by using the Laplace approximation, and
the correlation structure within the random effects has only an
additional constraint: the variance-covariance matrix must be
symmetric and positive semidefinite [20].
To construct these models, the absence or lowest level of
exposure was taken as the reference category. We performed a
bivariate analysis, using the variables of exposure and potential
confounders; and a multivariate analysis, including those inde-
pendent variables which yielded a statistical significance of less
than 0.2 in the bivariate analysis. The independent variables with
the highest level of statistical significance were successively
eliminated from the original model, provided that the coefficients
of the principal variables of exposure changed by no more than
10% and Schwarz’s Bayesian Information Criterion.
In addition to each antidepressant group, the following variables
were included in the model: alcohol and caffeine consumption,
past history of GI disorders, family history of GI bleeding,
osteoarthritis, number of medicines taken and the use of NSAIDs,
salicylates (analgesic doses), proton pump inhibitors, H2 antihis-
tamines, antacids, antiplatelet agents and anticoagulants (only
vitamin K antagonists).
The protocol of the study was approved by the corresponding
Ethics Committees of the participating hospitals. All patients were
asked for an informed consent and, to be included in the study,
they had to give a written informed consent.
Results
Out of 4325 patients who were interviewed, 1939 were finally
considered eligible for the study: 581 cases of upper GI bleeding
and 1358 controls; 2386 patients were excluded for not meeting
the case or control definition (2169 cases and 217 controls) and
146 (32 cases and 114 controls) explicitly refused to participate.
Frequent clinical signs of the cases were: melena (86.3%), dizziness
(59.2%), asthenia (56.3%) or hematemesis (40.7%). Corresponding
controls were 704 (51.8%) patients admitted for cataract surgery
and 329 (24.2%) patients with non painful inguinal hernias; the
remaining were patients admitted for varicectomy, prostate
adenoma surgery, septoplasty, lipoma removal and others. The
median time from hospital admission until interview was 2 days for
cases and 0 days for controls.
Distribution of prognostic factors between cases and controls
after matching is presented in Table 1. No differences in age or sex
distribution were observed between cases and controls after
matching. Overall, 4.0% of the cases and 3.3% of controls used
an SSRI antidepressant in the week before the index day. No
SSRIs and Gastrointestinal Bleeding
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significant risk of upper GI bleeding was encountered for SSRI
antidepressants (adjusted OR, 1.06, 95% CI, 0.57–1.96) or for
whichever other grouping of antidepressants (Table 2).
The proportion of patients exposed to NSAIDs was 21.9% for
cases and 7.6% for controls; adjusted OR for NSAIDs was 4.36
(95% CI, 3.11–6.13). Prevalence of self-medication with NSAIDs
or analgesic doses of salycilates was 7.5% (cases, 15.5%; controls,
4.1%); this was slightly more frequent in those having SSRI
antidepressants than in those not having these medications (8.8%
vs. 7.5%). Self-medication with NSAIDs or analgesic doses of
salycilates had no influence on final estimates; when the analysis
was restricted to non self-medicated patients, the risk of upper GI
bleeding associated with SSRIs neither was modified (adjusted
OR, 0.97, 95% CI, 0.50–1.87). Eight patients were simultaneously
taking SSRIs and NSAIDs (4 cases and 4 controls).
Acid-suppressing drugs (proton pump inhibitors or H2 antihis-
tamines) were taken by 11.9% of the cases and 17.1% of the
controls; the adjusted ORs for proton pump inhibitors were 0.42
(95% CI, 0.29–0.63) and 0.33 (95% CI, 0.17–0.65) for H2
antihistamines. Cases and controls receiving SSRIs had also more
acid-suppressing drugs than non-SSRI users (22.1% vs. 15.3%).
Similarly, when the analysis was restricted to those patients not
taking acid-suppressing drugs, results did not change (SSRIs
adjusted OR for upper GI bleeding, 1.11, 95% CI, 0.56–2.18).
Discussion
When our study protocol was first prepared, four studies had
been published [2–5]; three of those studies found odds ratios of 3
or more and only one, clearly heterogeneous in design, found no
risk [3]; thus, our study had power to detect an odds ratio of 2 and
failed to detect an association between SSRI exposure and
occurrence of upper GI bleeding of this magnitude; in it, we have
found a clear association with NSAIDs in the range of that
reported in the literature [21]. When considering the different
groupings of antidepressants there were no differences. This is
consistent with the results of another case-control study similarly
conducted with the same protocol and in a close similar healthcare
setting [10]. Out of 15 studies conducted so far (Table 3), 4 found
a strong significant association (a relative risk value higher than 2)
[2,5,7,11], 5 found a significant mild association (a risk value
between 1 and 1.7) [9,12,13,15,16] and 5 did not find any
association at all [3,8,10,14, present study]; in the remaining two
studies, the outcome variables were not entirely comparable to
those of the other studies, but a trend to an increased risk was
observed with increased serotonin inhibition reuptake [4,6]. Since
all these studies have been conducted during different periods, in
different geographical areas and healthcare settings, with different
designs and different ways of collecting information, the
explanation of those different estimates may lie on this
heterogeneity; nevertheless, retrospective or prospective character
seems to be a remarkable factor of heterogeneity (Table 3); thus,
only 1 out of 4 prospective studies published so far found a
significant risk while, in the retrospective studies, it was 9 in 12
which found a significant risk. It is possible that, since most of these
retrospective studies have been conducted with pre-existing
information –not collected for the purposes of these particular
studies– some relevant confounding factors might be difficult to
adjust for. For instance, in these studies neither there is
information upon intake of medication, nor upon exposure to
OTC drugs –depressive patients are more prone to self-medicate
[22], nor upon co-morbidities not stated that may lead to the
intake of non-prescription NSAIDs, nor, in some studies, upon
alcohol intake. In our study, we could control for self-medication
with NSAIDs; thus, when restricted to non self-medicated patients,
the risk slightly decreased denoting a certain influence of self-
medication. However, it cannot be ruled out that self-medication,
with a differential distribution between cases and controls, might
have some influence on other studies. Furthermore, it has been
pointed out that observational studies, in which cases are collected
from hospitals and controls are non-hospitalised patients, might be
affected by a selection bias [23]. In the study by de Abajo et al.
[12], the prevalence of current use for acid-suppressing drugs
(proton pump inhibitors or H2 antihistamines) was 19.5% in case
patients and 11.2% in controls (11.9% and 17.1%, respectively, in
our study); therefore, the authors state that these figures suggest an
important confounding factor by indication; in a broader
approach, they might be also interpreted as a risk marker denoting
differential severity between cases and controls impossible to fully
Table 1. Baseline characteristics.
Number (%)
Cases
(n=581)
Controls
(n=1358)
Crude OR
(95% CI)
Age (mean; SD) 62.6; 17.0 63.2; 15.7 Matching factor
Females 152 (26.2) 405 (29.8) Matching factor
BMI (mean; SD)a 26.6; 4.3 26.6; 4.0
Study yearsb 8.4; 4.5 7.9; 4.2
Smoking status
Non-smoker 249 (42.9) 635 (46.8) 1 (reference)
Ex-smoker 193 (33.2) 445 (32.7) 1.11 (0.88–1.38)
Current smoker 139 (23.9) 278 (20.5) 1.28 (0.99–1.64)
Caffeine consumption 490 (84.3) 1148 (84.5) 0.98 (0.75–1.29)
Alcohol intakec
No intake 197 (33.9) 475 (35.0) 1 (reference)
Mild 255 (43.9) 658 (48.5) 0.93 (0.75–1.16)
Moderate 99 (17.0) 196 (14.4) 1.22 (0.91–1.63)
Heavy 30 (5.2) 29 (2.1) 2.49 (1.46–4.27)
Family history of GI bleeding 150 (26.6) 229 (17.5) 1.71 (1.35–2.16)
Previous history of GI tract
disorders
None 225 (38.9) 660 (48.9) 1 (reference)
Dyspepsia 149 (25.8) 498 (36.9) 0.88 (0.69–1.11)
Ulcer 81 (14.0) 106 (7.8) 2.24 (1.62–3.11)
Bleeding 123 (21.3) 87 (6.4) 4.15 (3.03–5.67)
Co-morbidity
Diabetes 95 (16.4) 187 (13.8) 1.22 (0.93–1.60)
Heart disease 153 (26.8) 280 (20.8) 1.39 (1.11–1.75)
Hypertension 227 (39.1) 509 (37.8) 1.06 (0.87–1.29)
High cholesterol 174 (30.3) 381 (28.4) 1.10 (0.89–1.36)
Osteoarthritis 169 (30.7) 445 (35.0) 0.83 (0.67–1.02)
Intake of more than 3
medications
310 (53.4) 565 (41.6) 1.61 (1.32–1.95)
Distribution of cases and controls according to prognostic factors.
Abbreviations: OR, odds ratio; CI, confidence interval.
aFor Body Mass Index (BMI) there were 579 cases and 1354 controls available.
bFor study years there were 578 cases and 1354 controls available.
cAlcohol consumption: In women: low, #20 mg/day; moderate, between
.20 mg/day and #60 mg/day; high, .60 mg/day. In men: low, #30 mg/day;
moderate, between .30 mg/day and #80 mg/day; high, .80 mg/day.
doi:10.1371/journal.pone.0019819.t001
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adjust for in that study (crude estimate for acid-suppressing drugs
was 2.0 and 1.2 after adjustment). Selection bias is consistent with
the fact that none of the studies in which cases and controls came
from hospitals found a significant risk [8,10,14, present study].
Thus, a possible explanation for the risk detected in some studies
would be that, since depression is currently associated with more
morbidity and also with past use of antidepressants, these drugs in
turn might be spuriously associated with bleeding.
Had the SSRIs caused upper GI bleeding through a mechanism
related to serotonin reuptake inhibition, other bleeding complica-
tions might also appear; however, there is no consistency at this
regard. While two epidemiological studies upon abnormal
bleeding and perioperative blood transfusion, respectively, sug-
gested an increased risk related to SSRIs [6,24], in other 6 studies
upon hemorrhagic stroke [25–28], postpartum haemorrhage [29]
and hemorrhagic events in different locations [30], no association
was found.
Depletion of serotonin from platelets caused by SSRIs has been
currently postulated as the most likely mechanism for bleeding
[31]. Accordingly, inhibition by SSRIs of serotonin reuptake by
platelets is thought to lead to reduced platelet serotonin levels and
it would lead to diminished serotonin release from platelets on
activation and to decreased platelet aggregation. In the study by
Hergovich et al. [32], serotonin concentration in the platelets
decreased by 83% after 14 days of paroxetine use (20 mg/day) and
the platelet function analyser (PFA)-closure time was increased by
31%. Conversely, the results of other studies that have also
investigated the effect of SSRI treatment on platelet activity are
not consistent. McCloskey et al. [33], in a study comparing
patients treated with SSRIs (n = 32) and patients on bupropion
(n = 29), found significant platelet abnormalities by using platelet
aggregation and release assays but not when using the PFA-100
method. In another study, only 6 out of 43 patients treated with
different SSRIs had an abnormal platelet function (PFA-closure
time .150 s) [34]. A third study, comprising 12 healthy young
men, did not find any difference between sertraline and placebo
intake regarding platelet activity and serotonin uptake [35].
Furthermore, there is no a clear correlation between clinical
bleeding and platelet aggregation abnormalities; in a series of 35
patients with high-abnormal bleeding time, 21 (60%) had a normal
platelet function [36]. Recently, it has been suggested that SSRIs
added to platelet impaired function may have a direct harmful
effect on the GI tract mucosa based on observations by Takeuchi
et al. [37]. These authors did observe that paroxetine worsens the
development of antral ulcers induced by indomethacin in rats;
however, in the same experiments, it was similarly observed that
paroxetine, dose-dependently suppressed indomethacin-induced
gastric corpus and intestinal lesions, which precludes any firm
conclusions and requires further research.
The stringent definition of exposure, the carefully and thorough
information gathered and the objective ascertainment of the cases
are the main strength of our study; also, by using prompt cards –a
series of colour pictures including the drugs of interest, we could
avoid or highly reduce recall bias. Additionally, the statistical
analysis performed showed that the estimates values found by
applying a generalised linear mixed model or the conventional
logistic regression were grossly coincidental (footnote on Table 2).
On the contrary, the small percentage of patients having SSRIs
and NSAIDs simultaneously prevents the analysis of interaction;
also, the sample size does not permit to analyse by certain
subgroups or individual drugs. It is possible as well that, by using
hospitalized controls, we selected a sicker group as comparator;
however, the prevalence of SSRIs use among controls in our study
is close similar to figures for the general population in Spain [38].
Moreover, considering prevalence of acid-suppressing drugs as a
risk marker and assuming an imbalance in severity between our
cases and controls, it could be fully dealt with in the analysis since
we found expected estimates for acid-suppressing drugs when
adjusting (adjusted OR for proton pump inhibitors, 0.42, 95% CI,
0.29–0.63; adjusted OR for H2 antihistamines, 0.33, 95% CI,
0.17–0.65); likewise, the risk estimate for NSAID-induced upper
GI bleeding was as expected. Another limitation would be the
Table 2. Risk of upper gastrointestinal bleeding associated with the intake of antidepressants.
Number (%)
Categorya
Cases
(n =581)
Controls
(n =1358) Crude OR (95% CI)b Adjusted OR (95% CI)c
All antidepressants 33 (5.7) 74 (5.4) 1.04 (0.68–1.59) 0.91 (0.54–1.52)
High affinity 15 (2.6) 34 (2.5) 1.03 (0.56–1.91) 0.91 (0.43–1.93)
Intermediate affinity 17 (2.9) 36 (2.7) 1.11 (0.62–1.99) 1.11 (0.54–2.28)
Low affinity 3 (0.5) 12 (0.9) 0.58 (0.16–2.07) 0.48 (0.12–1.94)
SSRIs 23 (4.0) 45 (3.3) 1.20 (0.72–2.01) 1.06 (0.57–1.96)d
Non-SSRIs 7 (1.2) 23 (1.7) 0.71 (0.30–1.66) 0.87 (0.32–2.39)
Other antidepressants 6 (1.0) 15 (1.1) 0.93 (0.36–2.42) 0.45 (0.14–1.46)
Abbreviations: OR, odds ratio; CI, confidence interval.
aAntidepressants:
High affinity: fluoxetine, paroxetine, sertraline and clomipramine.
Intermediate affinity: amitriptyline, fluvoxamine, citalopram, imipramine, dosulepin, venlafaxine, duloxetine, escitalopram and melitracen.
Low affinity: mirtazapine, nortriptyline, desipramine, trimipramine, maprotiline, trazodone, mianserin, amoxapine, bupropion, doxepin, moclobemide, ciclobenzaprine
and etoperidone.
SSRIs: sertraline, fluoxetine, fluvoxamine, paroxetine, citalopram, etoperidone and escitalopram.
Non-SSRIs: amitriptiline, dosulepin, trimipramine, doxepine, maprotiline, amoxapine, imipramine, nortriptiline and clomipramine.
Other antidepressants: bupropion, ciclobenzaprine, desipramine, duloxetine, melitracen, mianserin, mirtazepine, moclobemide, trazodone and venlafaxine.
bAdjusted for matching factors: age, sex (65 years), date of admission (within 3 months) and hospital.
cAdjusted for alcohol and caffeine consumption, past history of GI disorders, family history of GI bleeding, osteoarthritis, number of medicines taken and use of NSAIDs,
salicylates (analgesic doses), proton pump inhibitors, H2 antihistamines, antacids, antiplatelet agents and anticoagulants (only vitamin K antagonists).
dWhen applying conventional logistic regression, the adjusted estimate for SSRIs was 1.24 (95%CI, 0.62–2.48).
doi:10.1371/journal.pone.0019819.t002
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possibility that patients in the study population with emergency
bleeds would go to different hospitals, and then undergo elective
surgeries; however, the base population is the same for both as the
elective surgery hospitals belong to the same population area
covered by the main hospitals. In addition, patients cannot select
the hospital where the surgical intervention will be performed; this
is planned by the National Health Service.
In summary, the results of this case-control study showed no
significant increase in upper GI bleeding with SSRIs and provide
good evidence that the magnitude of any increase in risk is not
greater than 2.
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